Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Juan Ma, Jennifer Dunlap, Aleksandra Paliga, Elie Traer, Richard Press, Lisong Shen & Guang Fan. (2018) DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. Leukemia & Lymphoma 59:8, pages 1938-1948.
Read now
Read now
Jack W Singer, Suliman Al-Fayoumi, Haiching Ma, Rami S Komrokji, Ruben Mesa & Srdan Verstovsek. (2016) Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. Journal of Experimental Pharmacology 8, pages 11-19.
Read now
Read now
Brian W Dymock & Cheng Shang See. (2013) Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012. Expert Opinion on Therapeutic Patents 23:4, pages 449-501.
Read now
Read now
Hideo Uchida, Koiti Inokuchi, Reiko Watanabe, Michihide Tokuhira & Masahiro Kizaki. (2008) New therapeutic approaches to acute myeloid leukemia. Expert Opinion on Drug Discovery 3:6, pages 689-706.
Read now
Read now
Michael Davies, Bryan Hennessy & Gordon B Mills. (2006) Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy 7:16, pages 2243-2261.
Read now
Read now
Articles from other publishers (29)
Huining Su, Mimi Wang, Xingchen Pang, Feng Guan, Xiang Li & Ying Cheng. 2021. Reviews of Physiology, Biochemistry and Pharmacology. Reviews of Physiology, Biochemistry and Pharmacology
85
117
.
Adrián Mosquera Orgueira, Laura Bao Pérez, Alicia Mosquera Torre, Andrés Peleteiro Raíndo, Miguel Cid López, José Á. Díaz Arias, Roi Ferreiro Ferro, Beatriz Antelo Rodríguez, Marta S. González Pérez, Manuel Albors Ferreiro, Natalia Alonso Vence, Manuel M. Pérez Encinas, José L. Bello López, Giovanni Martinelli & Claudio Cerchione. (2020) FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. Minerva Medica 111:5.
Crossref
Crossref
Mark Noble, Margot Mayer-Pröschel, Zaibo Li, Tiefei Dong, Wanchang Cui, Christoph Pröschel, Ibro Ambeskovic, Joerg Dietrich, Ruolan Han, Yin Miranda Yang, Christopher Folts, Jennifer Stripay, Hsing-Yu Chen & Brett M. Stevens. (2015) Redox biology in normal cells and cancer: Restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment. Free Radical Biology and Medicine 79, pages 300-323.
Crossref
Crossref
Anders Poulsen, Anthony D. William & Brian W. Dymock. 2014. Macrocycles in Drug Discovery. Macrocycles in Drug Discovery
141
205
.
Brian W Dymock, Eugene Guorong Yang, Yuyi Chu-Farseeva & Lianbin Yao. (2014) Selective JAK inhibitors. Future Medicinal Chemistry 6:12, pages 1439-1471.
Crossref
Crossref
Thomas Stiehl, Natalia Baran, Anthony D. Ho & Anna Marciniak-Czochra. (2014) Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse. Journal of The Royal Society Interface 11:94, pages 20140079.
Crossref
Crossref
Hai Wang, Haiyan Hu, Qian Zhang, Yadong Yang, Yanming Li, Yang Hu, Xiuyan Ruan, Yaran Yang, Zhaojun Zhang, Chang Shu, Jiangwei Yan, Edward K. Wakeland, Quanzhen Li, Songnian Hu & Xiangdong Fang. (2013) Dynamic transcriptomes of human myeloid leukemia cells. Genomics 102:4, pages 250-256.
Crossref
Crossref
Pamela Farrell, Lihong Shi, Jennifer Matuszkiewicz, Deepika Balakrishna, Takashi Hoshino, Lilly Zhang, Sarah Elliott, Robyn Fabrey, Bumsup Lee, Petro Halkowycz, BiChing Sang, Seigo Ishino, Toshiyuki Nomura, Mika Teratani, Yoshikazu Ohta, Charles Grimshaw, Bheema Paraselli, Takashi Satou & Ron de Jong. (2013) Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor. Molecular Cancer Therapeutics 12:4, pages 460-470.
Crossref
Crossref
Allen B. Williams, Li Li, Bao Nguyen, Patrick Brown, Mark Levis & Donald Small. (2012) Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood 120:15, pages 3069-3079.
Crossref
Crossref
Stuart S. Winter. (2011) Pediatric Acute Leukemia Therapies Informed by Molecular Analysis of High-Risk Disease. Hematology 2011:1, pages 366-373.
Crossref
Crossref
Anthony D. William, Angeline C.-H. Lee, Stéphanie Blanchard, Anders Poulsen, Ee Ling Teo, Harish Nagaraj, Evelyn Tan, Dizhong Chen, Meredith Williams, Eric T. Sun, Kee Chuan Goh, Wai Chung Ong, Siok Kun Goh, Stefan Hart, Ramesh Jayaraman, Mohammed Khalid Pasha, Kantharaj Ethirajulu, Jeanette M. Wood & Brian W. Dymock. (2011) Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma. Journal of Medicinal Chemistry 54:13, pages 4638-4658.
Crossref
Crossref
Prabal Banerjee, Lindsey Crawford, Elizabeth Samuelson & Gerold Feuer. (2010) Hematopoietic stem cells and retroviral infection. Retrovirology 7:1.
Crossref
Crossref
Eric Schafer & Donald Small. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy
56
76
.
Ken Mills. 2010. Diagnostic Techniques in Hematological Malignancies. Diagnostic Techniques in Hematological Malignancies
90
110
.
Ellen Christina Obermann, Caroline Arber, Martine Jotterand, Andre Tichelli, Petra Hirschmann & Alexandar Tzankov. (2010) Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Annals of Hematology 89:7, pages 663-669.
Crossref
Crossref
Piya Lahiry, Ali Torkamani, Nicholas J. Schork & Robert A. Hegele. (2010) Kinase mutations in human disease: interpreting genotype–phenotype relationships. Nature Reviews Genetics 11:1, pages 60-74.
Crossref
Crossref
Everson Augusto Krum, Mihoko Yamamoto & Maria de Lourdes Lopes Ferrari Chauffaille. (2009) Prevalence of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD+) in de novo acute myeloid leukemia patients categorized according to cytogenetic risk. Sao Paulo Medical Journal 127:1, pages 23-27.
Crossref
Crossref
Ronald Feitosa Pinheiro, Eloisa de Sá Moreira, Maria Regina Régis Silva, Fernando Lopes Alberto & Maria de Lourdes L.F. Chauffaille. (2008) FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genetics and Cytogenetics 183:2, pages 89-93.
Crossref
Crossref
Heiko Fensterer, Bernhard Radlwimmer, Jörn Sträter, Malte Buchholz, Daniela E Aust, Catherine Julié, François Radvanyi, Bernard Nordlinger, Claudio Belluco, Eric Van Cutsem, Claus-Henning Köhne, Hans A Kestler, Carsten Schwaenen, Michelle Nessling, Manfred P Lutz, Peter Lichter & Thomas M Gress. (2007) Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks. BMC Cancer 7:1.
Crossref
Crossref
KyeongJin Kim, Hyeong Hoe Kim, Joon Hong Kim, Yung Hyun Choi, Young Hee Kim & JaeHun Cheong. (2007)
Chemokine stromal cell-derived factor-1 induction by C/EBPβ activation is associated with all-
trans
-retinoic acid-induced leukemic cell differentiation
. Journal of Leukocyte Biology 82:5, pages 1332-1339.
Crossref
Crossref
Lisheng WangJie WangBradley W. BlaserAnne-Marie Duchemin, Donna F. KusewittTom Liu, Michael A. Caligiuri & Roger Briesewitz. (2007) Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 110:6, pages 2075-2083.
Crossref
Crossref
Jiong Hu, Guang‐Biao Zhou, Zhen‐Yi Wang, Sai‐Juan Chen & Zhu Chen. 2007.
191
220
.
Weina Chen, Georgios Z. Rassidakis & L. Jeffrey Medeiros. (2006) Nucleophosmin Gene Mutations in Acute Myeloid Leukemia. Archives of Pathology & Laboratory Medicine 130:11, pages 1687-1692.
Crossref
Crossref
Lisa J. Robinson, Jia Xue & Seth J. Corey. (2005) Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Experimental Hematology 33:4, pages 469-479.
Crossref
Crossref
Johan Lennartsson, Tanya Jelacic, Diana Linnekin & R. Shivakrupa. (2009) Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit. STEM CELLS 23:1, pages 16-43.
Crossref
Crossref
David W Sternberg & Jonathan D Licht. (2005) Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Current Opinion in Hematology 12:1, pages 7-13.
Crossref
Crossref
Eleanor J. Douglas, Heike Fiegler, Andrew Rowan, Sarah Halford, David C. Bicknell, Walter Bodmer, Ian P. M. Tomlinson & Nigel P. Carter. (2004) Array Comparative Genomic Hybridization Analysis of Colorectal Cancer Cell Lines and Primary Carcinomas. Cancer Research 64:14, pages 4817-4825.
Crossref
Crossref
Satei Moqattash & John D. Lutton. (2016) Leukemia Cells and the Cytokine Network: Therapeutic Prospects. Experimental Biology and Medicine 229:2, pages 121-137.
Crossref
Crossref
John T Reilly. (2003) Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Reviews 17:4, pages 241-248.
Crossref
Crossref